Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments

Eleni Kokkotou,Maximilian Anagnostakis,Georgios Evangelou,Nikolaos K Syrigos,Ioannis Gkiozos,Nikolaos K. Syrigos

DOI: https://doi.org/10.3390/cancers16071414

2024-04-05

Cancers

Abstract:Conventional cancer clinical trials can be time-consuming and expensive, often yielding results with limited applicability to real-world scenarios and presenting challenges for patient participation. Real-world data (RWD) studies offer a promising solution to address evidence gaps and provide essential information about the effects of cancer treatments in real-world settings. The distinction between RWD and data derived from randomized clinical trials lies in the method of data collection, as RWD by definition are obtained at the point of care. Experimental designs resembling those used in traditional clinical trials can be utilized to generate RWD, thus offering multiple benefits including increased efficiency and a more equitable balance between internal and external validity. Real-world data can be utilized in the field of pharmacovigilance to facilitate the understanding of disease progression and to formulate external control groups. By utilizing prospectively collected RWD, it is feasible to conduct pragmatic clinical trials (PCTs) that can provide evidence to support randomized study designs and extend clinical research to the patient's point of care. To ensure the quality of real-world studies, it is crucial to implement auditable data abstraction methods and develop new incentives to capture clinically relevant data electronically at the point of care. The treatment landscape is constantly evolving, with the integration of front-line immune checkpoint inhibitors (ICIs), either alone or in combination with chemotherapy, affecting subsequent treatment lines. Real-world effectiveness and safety in underrepresented populations, such as the elderly and patients with poor performance status (PS), hepatitis, or human immunodeficiency virus, are still largely unexplored. Similarly, the cost-effectiveness and sustainability of these innovative agents are important considerations in the real world.

oncology

What problem does this paper attempt to address?

The main problem this paper attempts to address is:

In the field of lung cancer treatment, traditional clinical trials (RCTs) have issues such as long duration, high cost, and limited applicability, especially in real-world applications. Therefore, this paper explores how to use real-world data (RWD) to generate real-world evidence (RWE) to compensate for the shortcomings of traditional clinical trials and provide broader and more practical information on lung cancer treatment.

Specifically, the paper focuses on the following aspects:

1. **The role of RWD and RWE in lung cancer research**:
- RWD studies can provide a large number of samples, faster research results, and lower costs, thereby improving the generalizability and practicality of the research.
- RWD studies, by collecting and analyzing observational data, provide insights into the application of lung cancer treatment in actual clinical settings.

2. **Quality and reliability of RWD**:
- Low-quality RWD may affect the reliability of RWE, so it is necessary to ensure the quality of the data, including data acquisition, cleaning, standardization, etc.
- Mixed methodological analysis (R2WE) combines the advantages of RCTs and RWD to improve the reliability of the evidence.

3. **Application of RWE in drug development and regulation**:
- RWE can be used to support the approval process of new drugs, especially in identifying rare side effects and assessing long-term safety.
- RWE can also help optimize clinical trial design, reduce exclusion criteria restrictions, and improve patient recruitment rates.

4. **RWE for specific populations**:
- Elderly patients, patients with poor performance status, patients with chronic viral infections, and patients with brain metastases are often excluded from traditional clinical trials. RWE can provide data on the treatment effects and safety for these specific populations.
- For example, for patients with a performance status of 2, RWE shows the efficacy and safety of immune checkpoint inhibitors (ICIs).

5. **RWE of immune checkpoint inhibitors (ICIs)**:
- ICIs have made significant progress in lung cancer treatment, but data on their application in specific populations are still lacking. RWE can help fill these gaps, providing detailed information on the efficacy and safety of ICIs in different populations.

In summary, this paper aims to provide more comprehensive and practical evidence for clinical decision-making, drug development, and regulation by exploring the application of RWD and RWE in lung cancer research.